Abbott Issues Updated 2021 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Abbott Laboratories (ABT) Falls After Cutting Full-Year Outlook on Lower Demand for Covid-19 Tests
June 1, 2021 10:56 AM EDTShares of Abbott Laboratories (NYSE: ABT) are down 6.5% in todays trading session after the company issued an updated 2021 outlook to reflect lower demand from its diagnostic unit.
The company cited significantly lower recent and projected COVID-19 diagnostic testing demand amid an accelerated vaccination activity.
Hence, the company now expects full-year 2021 EPS of $2.75 to $2.95 and full-year adjusted EPS of $4.30 to $4.50, below the consensus of... More
